AzacitidineThird Party Manufacturing in India

Azacitidine is a pyrimidine nucleoside analog of cytidine that acts as a hypomethylating agent for the treatment of myelodysplastic syndromes and acute myeloid leukemia. It is a prodrug that enters cells through nucleoside transporters and undergoes three successive phosphorylation steps to form the active metabolite, azacitidine triphosphate. About 80 to 90 percent of the drug is incorporated into RNA, disrupting RNA metabolism and protein synthesis. The remaining 10 to 20 percent is converted by ribonucleotide reductase to 5-aza-2'-deoxycytidine triphosphate, which is then incorporated into DNA during replication. Once incorporated into DNA, it forms irreversible covalent adducts with DNA methyltransferase 1 (DNMT1), the enzyme responsible for maintaining DNA methylation patterns. This traps and depletes DNMT1, leading to progressive loss of DNA methylation — a process called hypomethylation — as cells divide. Reduced DNA methylation reactivates previously silenced tumor suppressor genes, restoring their normal function in regulating cell differentiation, proliferation, and apoptosis. Azacitidine thereby reverses the abnormal epigenetic silencing that drives the growth of cancerous bone marrow cells. At higher concentrations, its cytotoxic effects directly kill rapidly dividing leukemia cells. This dual mechanism — epigenetic modulation through DNMT1 inhibition and direct cytotoxicity — makes azacitidine effective against hematological malignancies that rely on aberrant DNA methylation for survival and proliferation.

Azacitidine is a hypomethylating agent used primarily for the treatment of myelodysplastic syndromes and acute myeloid leukemia. It is available as a lyophilized powder for injection in 100 mg/vial strength for subcutaneous or intravenous administration.

Therapeutic Uses

• Myelodysplastic Syndromes (MDS): Approved for all French-American-British (FAB) MDS subtypes including refractory anemia, refractory anemia with ringed sideroblasts (with cytopenias), refractory anemia with excess blasts (RAEB), RAEB in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL)
• Acute Myeloid Leukemia (AML): Used in older adult patients with AML who are not candidates for intensive induction chemotherapy, particularly those with 20 to 30 percent bone marrow blasts
• Epigenetic Therapy: Cornerstone of epigenetic treatment for myeloid malignancies, offering a valuable alternative for patients who cannot tolerate aggressive chemotherapy regimens

Why Manufacturers Choose Azacitidine

Azacitidine is a high-value oncology injectable with strong demand driven by the increasing incidence of MDS and AML in aging populations worldwide. The molecule requires specialized sterile manufacturing with lyophilization capabilities and cold chain management expertise. Indian manufacturers with WHO-GMP certified injectable facilities can serve both domestic hospital demand and regulated export markets including the US and EU. The 100 mg/vial presentation is the global standard dosage form, and production requires expertise in aseptic processing.

This makes Azacitidine one of the most sought-after molecules for third party manufacturing in India, with consistent demand from oncology centers, PCD franchise operators, and export-oriented pharmaceutical companies.